Key opinion leaders discuss how patient quality of life is impacted by MDS treatment-associated challenges.
The discussion delves into the multifaceted impact of myelodysplastic syndromes (MDS) on patients, treatment approaches, and the challenges they pose. Highlighting the stark differences between low and high-risk MDS patients, the conversation underscores the significant anxieties and management needs for those requiring frequent transfusions. The logistical complexities of routine blood tests leading to potential transfusions profoundly affect patients' lives, posing economic burdens due to missed workdays and necessitating caregiver support.
Dr. Birhiray emphasizes the profound burden on patients, highlighting how clinicians may not always recognize the extent of these challenges. Absenteeism's real impact on employee well-being is noted, emphasizing the broader implications beyond individual patient care.
The critical consideration of treatment options between intravenous (IV) and oral therapies is discussed in the context of MDS being a lifelong condition without a cure. The discussion revolves around patient compliance and the need for more convenient treatment methods. Dr. Birhiray stresses the importance of engaging patients in shared decision-making regarding therapy options, acknowledging the significance of holistic care beyond medication in MDS management.
The conversation underscores the economic considerations, including travel for treatments in rural areas and the need for medical policy understanding among healthcare directors. Overall, the discussion stresses the need for tailored, patient-centric approaches in MDS management that encompass treatment convenience, economic impact, and the broader landscape of care.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.